Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease

Abstract

Gaucher disease (GD) is a lysosomal storage disease caused by the deficiency of glucocerebrosidase characterized by a broad spectrum of clinical manifestations including hepatosplenomegaly, bone infiltration, and cytopenia, and even central nervous system involvement. Bone manifestations are typical of the GD-I and partially responded to mainstay therapy. Ambroxol (ABX), an approved cough-suppressant, was identified as an enzyme-enhancement agent of the residual activity of glucocerebrosidase mutants derived from different misfolding-mutations in the GBA gene. Here, we describe the early beneficial effects of ABX on skeletal and hematological manifestations of a child suffering with progressive GD-I.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2

References

  1. 1.

    Charrow J, Dulisse B, Grabowski GA, Weinreb NJ. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet. 2007;71:205–11.

    Article  CAS  Google Scholar 

  2. 2.

    Ida H, Rennert OM, Kato S, Ueda T, Oishi K, Maekawa K. et al. Severe skeletal complications in Japanese patients with type 1 Gaucher disease. J Inherit Metab Dis. 1999;22:63–73.

    Article  CAS  Google Scholar 

  3. 3.

    El-Beshlawy A, Ragab L, Youssry I, Yakout K, El-Kiki H, Eid K, et al. Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients. J Inherit Metab Dis. 2006;29:92–8.

    Article  CAS  Google Scholar 

  4. 4.

    Mehta A. Epidemiology and natural history of Gaucher's disease. Eur J Intern Med. 2006;17:S2–5.

    Article  CAS  Google Scholar 

  5. 5.

    Liao HC, Chiang CC, Niu DM, Wang CH, Kao SM, Tsai FJ, et al. Detecting multiple lysosomal storage diseases by tandem mass spectrometry—a national newborn screening program in Taiwan. Clin Chim Acta. 2014;431:80–6.

    Article  CAS  Google Scholar 

  6. 6.

    Kang L, Zhan X, Gu X, Zhang H. Successful newborn screening for Gaucher disease using fluorometric assay in China. J Hum Genet. 2017;62:763–8.

    Article  CAS  Google Scholar 

  7. 7.

    Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, et al. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry. Am J Hematol. 2017;92:929–39.

    Article  CAS  Google Scholar 

  8. 8.

    Giraldo P, Perez-Lopez J, Nunez R, de la Puebla RF, Luno E, Saura-Grau S. et al. Patients with type 1 Gaucher disease in Spain: A cross-sectional evaluation of health status. Blood Cells Mol Dis. 2016;56:23–30.

    Article  Google Scholar 

  9. 9.

    Baldini M, Casirati G, Ulivieri FM, Cassinerio E, Khouri Chalouhi K, Poggiali E, et al. Skeletal involvement in type 1 Gaucher disease: not just bone mineral density. Blood cells Mol Dis. 2018;68:148–52.

    Article  CAS  Google Scholar 

  10. 10.

    Maegawa GH, Tropak MB, Buttner JD, Rigat BA, Fuller M, Pandit D. et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem. 2009;284:23502–16.

    Article  CAS  Google Scholar 

  11. 11.

    Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol. 2008;4:1119–29.

    Article  CAS  Google Scholar 

  12. 12.

    Narita A, Shirai K, Itamura S, Matsuda A, Ishihara A, Matsushita K, et al. Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study. Ann Clin Transl Neurol. 2016;3:200–15.

    Article  CAS  Google Scholar 

  13. 13.

    Choy FY, Zhang W, Shi HP, Zay A, Campbell T, Tang N, et al. Gaucher disease among Chinese patients: review on genotype/phenotype correlation from 29 patients and identification of novel and rare alleles. Blood Cells Mol Dis. 2007;38:287–93.

    Article  CAS  Google Scholar 

  14. 14.

    Liou B, Kazimierczuk A, Zhang M, Scott CR, Hegde RS, Grabowski GA. Analyses of variant acid beta-glucosidases: effects of Gaucher disease mutations. J Biol Chem. 2006;281:4242–53.

    Article  CAS  Google Scholar 

  15. 15.

    Nagy N. Establishment of EBV-infected lymphoblastoid cell lines. Methods Mol Biol. 2017;1532:57–64.

    Article  CAS  Google Scholar 

  16. 16.

    Mikosch P, Hughes D. An overview on bone manifestations in Gaucher disease. Wien Med Wochenschr. 2010;160:609–24.

    Article  Google Scholar 

  17. 17.

    Revel-Vilk S, Szer J, Mehta A, Zimran A. How we manage Gaucher disease in the era of choices. Br J Haematol. 2018;182:467–80.

    Article  Google Scholar 

  18. 18.

    Hruska KS, Goker-Alpan O, Sidransky E. Gaucher disease and the synucleinopathies. J Biomed Biotechnol. 2006;2006:78549.

    Article  CAS  Google Scholar 

  19. 19.

    Magalhaes J, Gegg ME, Migdalska-Richards A, Schapira AH. Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons. Sci Rep. 2018;8:1385.

    Article  CAS  Google Scholar 

  20. 20.

    Fois G, Hobi N, Felder E, Ziegler A, Miklavc P, Walther P. et al. A new role for an old drug: Ambroxol triggers lysosomal exocytosis via pH-dependent Ca(2)(+) release from acidic Ca(2)(+) stores. Cell Calcium. 2015;58:628–37.

    Article  CAS  Google Scholar 

  21. 21.

    Malerba M, Ponticiello A, Radaeli A, Bensi G, Grassi V. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharm Ther. 2004;17:27–34.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank the patient and her guardians to be included in this study.

Funding

This project is supported by Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20152520), Shanghai Science and Technology Committee (16JC1404600), NSFC (81570516), and National Key Research and Development Program (2016YFC0905100, 2016YFC0901505).

Author information

Affiliations

Authors

Contributions

Study design: WJ, MY, and HZ: data collection and data analysis; HZ and GM: data interpretation, drafting manuscript, approving final version of manuscript; HZ takes responsibility for the integrity of the data analysis.

Corresponding author

Correspondence to Huiwen Zhang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jiang, W., Yi, M., Maegawa, G.H.B. et al. Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease. J Hum Genet 65, 345–349 (2020). https://doi.org/10.1038/s10038-019-0704-3

Download citation

Search

Quick links